Hereditary Amyloidosis Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Hereditary Amyloidosis Market is segmented By Drug Type (RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Transthyretin (TTR) Stabilizers), By Route of Administration (Intravenous, Administration, Subcutaneous Administration, Oral Administration), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.

Hereditary Amyloidosis Market is segmented By Drug Type (RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotides, Transthyretin (TTR) Stabilizers), By Route of A ....

Hereditary Amyloidosis Market Size

Market Size in USD

CAGR11.8%

Study Period	2024 - 2031
Base Year of Estimation	2023
CAGR	11.8%
Market Concentration	High
Major Players	Alnylam Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, Akcea Therapeutics, Prothena Corporation

*Disclaimer: Major players are listed in no particular order.

*Source: Coherent Market Insights

Want to purchase customized report?
please let us know !

Hereditary Amyloidosis Market Analysis

The hereditary amyloidosis market is estimated to be valued at USD 1.23 Bn in 2024 and is expected to reach USD 2.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 11.8% from 2024 to 2031. The increasing prevalence of hereditary amyloidosis around the world along with growing awareness regarding the disease and its treatment options among the patients are fueling the market growth.

Hereditary Amyloidosis Market Report Snapshots

Buy Now